DENVER–(BUSINESS WIRE)–Dec 12, 2011 – Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to announce a second patient suffering skin cancer is self-administering cannabis extracts in collaboration with Cannabis Science. This patient has photo-documented dramatic results that we will be release to the public once treatment is completed and has been properly vetted by clinical biopsy. Cannabis Science, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who were seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed cancer treatment.
Cannabis has an outstanding safety profile as determined in 1988 by Federal Administrative Law Judge Francis Young who recommended cannabis be removed from Schedule I. The refusal of the DEA to follow this recommendation has resulted in 16 states allowing some form of medical marijuana access for their citizens. Numerous other states are moving in this direction. Consequently, patients in states with medical marijuana laws are able to make an informed decisions to try various state-legal cannabis preparations and to determine what is most effective for their particular condition. As a result, there is an unprecedented accumulation of“anecdotal” data
Currently, there are a variety treatments available for treating various skin cancers including standard surgical excision (Mohs Surgery), chemotherapy, radiation, and cryosurgery. Unfortunately for many, the cancer frequently returns and requires additional treatments. Chemo and radiation therapy are typically used by patients who aren’t candidates for surgery (i.e. where surgical excision could disfigure or make it difficult to reconstruct the excised area). If reoccurrence occurs, radiation therapy is often not repeated as it may further damage the tissue lead to resistance.
While the above treatments may to be effective for many, few patients would choose to go through surgical procedures, radiation, or chemotherapy if a better alternative were available. Patients self-administering cannabis extracts in the convenience of their own home appear to be effectively resolving their cancerous lesions over a period of a few weeks to a few months.
Cannabis Science is committed to making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today’s modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.
Please visit www.cannabisscience.com to view the “Breaking News”of the successful results and images of the self-administered cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.